Clinical cancer genomics company specializing in liquid biopsy
Clinical cancer genomics company specializing in liquid biopsy. Its circulating tumor DNA (ctDNA) tests use blood samples to detect and characterize cancer-related mutations, support earlier cancer detection and therapy selection, and monitor treatment response, minimal residual disease, and recurrence. Acquired by NeoGenomics in 2021.